Our Faculty

Scientists collaberate while working at a computer

With 130+ physician and research faculty members, our division is one of the largest in the country. Our faculty members participate in every facet of cancer prevention, patient care, survivorship, mentorship, and research on cancer and related diseases.

This is unpublished

Physician & Research Faculty Profiles 

View All Profiles

 

Notable Faculty achievements

  • Faculty have been elected by their peers to lead the American Society for Clinical Oncology, the American Society of Hematology, the American Association for Cancer Research, the American Society for Transplantation and Cellular Therapy, the World Marrow Donor Association, the American Society for Blood and Marrow Transplantation, and the National Cancer Institute’s Leukemia and Lymphoma Steering Committees.
  • Many faculty members have been chosen to determine standardized cancer care guidelines through the National Comprehensive Cancer Network.
  • Faculty have been editors-in-chief of major textbooks and professional journals.
  • Faculty published more than 400 peer-reviewed journal articles in 2019.
  • Our faculty continue to be chosen by their peers for Seattle Magazine’s Best Doctors list. In 2022 twelve faculty members were honored.
  • Sixteen faculty members hold endowed chairs. 
  • Our division was founded by Dr. E. Donnall Thomas, who received the Nobel Prize for his work in developing bone marrow transplantation.

Faculty news

Evergreen Fund Awardees
Evergreen Fund Awardees
Three researchers from the Dept. of Medicine have received funding from the Evergreen Fund, an internal grant program to advance translational discoveries.
Kate Markey named Innovators Network Endowed Chair
Kate Markey named Innovators Network Endowed Chair
Established by a community of next-generation donors, the endowed chair gives an early-career scientist the freedom to pursue bold ideas.
FDA approves new breast cancer drug based on VIKTORIA-1 study results
FDA approves new breast cancer drug based on VIKTORIA-1 study results
New targeted drug brings ‘big change, big benefit,’ per Fred Hutch’s Dr. Sara Hurvitz, who led the study.